GlassScriptPhysician profile
Ben Persons Bradenham
NPI 1326350570
$10,354.07
in general payments reported to CMS, 2019-2025
34 companies · $2,770 in 2025
The $2,770 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $750 · 2020: $399 · 2021: $734 · 2022: $914 · 2023: $2,134 · 2024: $2,652 · 2025: $2,770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,430 · Travel and Lodging: $3,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,429.57 |
| Travel and Lodging | $3,127.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,730.60 | 2019-2025 | Rinvoq, Skyrizi, Viberzi |
| Olympus Corporation of The Americas | $1,792.49 | 2025 | Disposable Distal Attachment, Single Use Electrosurgical Knife Kd-655, Olympus |
| Enterra Medical, INC. | $1,438.09 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $899.60 | 2019-2025 | Xifaxan, Trulance |
| Apollo Endosurgery US INC | $779.78 | 2023 | Overstitch Endoscopic Suturing System |
| Takeda Pharmaceuticals U.S.A., INC. | $671.26 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $459.42 | 2021-2025 | Tremfya, Stelara |
| Medtronic, INC. | $220.30 | 2024 | Endoflip |
| Ethicon US, LLC | $213.94 | 2023-2024 | Linx Reflux Management System, Linx Reflux Management System |
| Genzyme Corporation | $182.10 | 2019-2025 | |
| Celgene Corporation | $114.54 | 2021-2023 | Zeposia |
| Qol Medical, LLC | $102.95 | 2019-2024 | Sucraid, Sucraid |
| Lilly USA, LLC | $91.61 | 2025 | Omvoh |
| Pfizer INC. | $78.35 | 2019-2024 | |
| Ardelyx, INC. | $66.99 | 2022-2025 | Ibsrela |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $51.44 | 2022-2023 | Suflave |
| Ironwood Pharmaceuticals, INC | $48.09 | 2020-2021 | |
| Redhill Biopharma INC. | $39.00 | 2020 | |
| Curium US LLC | $34.75 | 2024 | Detectnet |
| Alnylam Pharmaceuticals INC. | $34.65 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $33.82 | 2024 | Voquezna |
| Amgen INC. | $33.53 | 2023 | Amjevita, Avsola |
| Sandoz INC. | $29.77 | 2023 | |
| Daiichi Sankyo INC. | $26.17 | 2024 | Injectafer |
| Shield Therapeutics INC | $25.17 | 2023 | Accrufer |
| Ucb, INC. | $24.10 | 2020 | |
| Alexion Pharmaceuticals, INC. | $23.82 | 2022 | |
| Intercept Pharmaceuticals, INC. | $23.59 | 2024 | |
| Merck Sharp & Dohme LLC | $17.29 | 2021 | |
| Endogastric Solutions, INC | $15.66 | 2019 | |
| Novo Nordisk INC | $15.04 | 2025 | Wegovy |
| Gilead Sciences, INC. | $14.05 | 2021 | |
| Nestle Healthcare Nutrition INC. | $12.33 | 2021 | |
| Organon LLC | $9.78 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ben Bradenham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.